Nuclear Medicine/Radiopharmaceuticals Market: Overview
The increasing prevalence of Cancer,
failure of Cardiac, Alzheimer’s, and Parkinson’s are some of the
important factor propelling the growth of the global market for nuclear
medicine and radiopharmaceuticals market in near future. Rising demand
from the growing economies is expected to influence the demand of this
market during the course of the forecast period from 2015 to 2023.
Furthermore, increasing demand for proper healthcare infrastructure, the
non-invasive nature of the process and increasing investment on
healthcare in this growing countries is likely to upsurge the demand of
this market, positively. The nuclear medicine and radiopharmaceuticals
market is further driven by spreading awareness at global level, major
progress in development of the radiotracers and the new pipeline of
radioisotopes.
On the other hand, very short term life
of the radiopharmaceuticals, unavailability of the reimbursement policy
and strict policy and rule are some of the factor hampering the growth
of the market at global level. The radiation exposure side effects is
also one of the important factor driving the demand negatively. The
major side effects of the radiation are infertility among men, skin
irritation, vomiting, fatigue and nausea.
The global market for nuclear medicine
and radiopharmaceuticals can be classified on the basis of the product
types and applications. Among all segment, cardiology of the application
segments dominates the market in terms of largest market share.
Whereas, SPECT of the product types segments expected to account for
major share of the market in nuclear medicine and radiopharmaceuticals
market in coming years.
Nuclear Medicine/Radiopharmaceuticals Market: Trends
The dependency and importance of the
diagnosing disease is one of the major factor significantly driving the
demand of the nuclear medicine and radiopharmaceuticals market. The
radiopharmaceuticals also helps in diagnosis the heart rate, the
mechanism process of kidney cells. The radiopharmaceuticals helps in
diagnosing metal health of the patients and it also helps in diagnosing
the exact location of bone fracture and the cancers location.
Nuclear Medicine/Radiopharmaceuticals Market: Geography
On the basis of geography, North America
is likely to dominate the global market for nuclear medicine and
radiopharmaceuticals in terms of usage. The effectiveness of the
diagnosis procedure for the early detection of the disease like cancer,
cardiac disease is important factor influencing the growth of this
market in near future. In 2014, market is dominated by the North America
and which is further followed by Europe and Asia Pacific. Furthermore,
North America likely to remain dominant due to its increased better
infrastructure facility in the healthcare sector, increasing cases of
the cancers and cardiac , the increasing advantages that the
radiopharmaceuticals have to provide and easy access to
radiopharmaceuticals.
Nuclear Medicine/Radiopharmaceuticals Market: Competition
This section of the report highlights the
major players operating in the global nuclear medicine and
radiopharmaceuticals market. The report also includes some of the
leading manufacturers operating in this market such as Sigma Aldrich
Corporation, Cardinal Health, Inc., IBA Molecular Imaging, Monrol
Nuclear Products and Mallinckrodt Plc.
The study also presents comprehensive
analysis of the competitive landscape and key opportunities it could
provide during the forecast period from 2015 to 2023
The report offers a comprehensive
evaluation of the market. It does so via in-depth qualitative insights,
historical data, and verifiable projections about market size. The
projections featured in the report have been derived using proven
research methodologies and assumptions. By doing so, the research report
serves as a repository of analysis and information for every facet of
the market, including but not limited to: Regional markets, technology,
types, and applications.
No comments:
Post a Comment